Literature DB >> 11081607

Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice.

D R Trune1, J B Kempton, M Kessi.   

Abstract

HYPOTHESIS: Although the glucocorticoid prednisone is the standard therapy for autoimmune sensorineural hearing loss, what this hormone does in the ear to restore hearing is not known. MRL/MpJ-Fas(lPr) autoimmune mice consistently have shown only stria vascularis disease, implying that abnormal ion balances in the endolymph underlie cochlear dysfunction. Previously we have shown that hearing loss in these mice is reversed with prednisolone treatment. This, coupled with the complete lack of cochlear inflammation, suggests that the restoration of hearing with prednisolone is due to its sodium transport function and not to its anti-inflammatory or immune suppression effects. Therefore the hypothesis of this study was that the mineralocorticoid aldosterone, which only increases sodium transport, would be as effective as prednisolone in reversing autoimmune hearing loss. STUDY
DESIGN: MRL/MpJ-Fas(lPr) autoimmune mice were treated with either prednisolone or aldosterone to compare steroid effects on auditory brainstem response (ABR) thresholds and stria morphology.
METHODS: After baseline ABR audiometry, autoimmune mice were given prednisolone (5 mg/kg per day), aldosterone (15 microg/kg per day), or water in their drinking bottles. After 2 months of treatment the ABR thresholds were remeasured, and ears collected for histological examination.
RESULTS: The untreated controls showed continued elevation of ABR thresholds and edematous stria. However, thresholds in most steroid mice were improved or unchanged and their stria morphology improved, particularly with aldosterone treatment.
CONCLUSIONS: Restoration of hearing with steroid treatment is due to increased sodium transport to re-establish cochlear ionic balances. Aldosterone therapy may offer advantages over prednisone for long-term management of not only autoimmune hearing loss, but also other forms of nonimmune-related deafness for which steroids are currently prescribed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11081607     DOI: 10.1097/00005537-200011000-00025

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  14 in total

1.  Therapy of hearing disorders - conservative procedures.

Authors:  Stefan Plontke
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

Review 2.  Immunosuppressive therapy for autoimmune inner ear disease.

Authors:  Maria C Buniel; Katie Geelan-Hansen; Peter C Weber; Vincent K Tuohy
Journal:  Immunotherapy       Date:  2009-05       Impact factor: 4.196

3.  Vascular Pathophysiology in Hearing Disorders.

Authors:  Dennis R Trune; Anh Nguyen-Huynh
Journal:  Semin Hear       Date:  2012-08

4.  Neuroprotective factors and incident hearing impairment in the epidemiology of hearing loss study.

Authors:  Adam J Paulsen; Karen J Cruickshanks; Alex Pinto; Carla R Schubert; Dayna S Dalton; Mary E Fischer; Barbara E K Klein; Ronald Klein; Michael Y Tsai; Ted S Tweed
Journal:  Laryngoscope       Date:  2019-01-30       Impact factor: 3.325

5.  Intratympanic dexamethasone injections for refractory Meniere' s disease.

Authors:  Hongmiao Ren; Tuanfang Yin; Yongde Lu; Weijia Kong; Jihao Ren
Journal:  Int J Clin Exp Med       Date:  2015-04-15

6.  Transtympanic corticoid therapy for acute profound hearing loss.

Authors:  Jürgen Lautermann; Holger Sudhoff; Rüdiger Junker
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-03       Impact factor: 2.503

Review 7.  Function of the audiovestibular system in children with systemic lupus erythematosus.

Authors:  Ghada Ibrahim Gad; Hanan Abdelateef
Journal:  Curr Allergy Asthma Rep       Date:  2014-07       Impact factor: 4.806

Review 8.  Corticosteroid therapy for hearing and balance disorders.

Authors:  Dennis R Trune; Barbara Canlon
Journal:  Anat Rec (Hoboken)       Date:  2012-10-08       Impact factor: 2.064

9.  Longitudinal results with intratympanic dexamethasone in the treatment of Ménière's disease.

Authors:  Maria Soledad Boleas-Aguirre; Frank R Lin; Charles C Della Santina; Lloyd B Minor; John P Carey
Journal:  Otol Neurotol       Date:  2008-01       Impact factor: 2.311

10.  Strial microvascular pathology and age-associated endocochlear potential decline in NOD congenic mice.

Authors:  Kevin K Ohlemiller; Mary E Rybak Rice; Patricia M Gagnon
Journal:  Hear Res       Date:  2008-08-12       Impact factor: 3.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.